Compare DOGZ & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | XOMAO |
|---|---|---|
| Founded | 2003 | N/A |
| Country | China | United States |
| Employees | N/A | 13 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.9M | N/A |
| IPO Year | 2017 | N/A |
| Metric | DOGZ | XOMAO |
|---|---|---|
| Price | $10.82 | $25.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 140.0K | N/A |
| Earning Date | 10-17-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,707,707.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.47 | N/A |
| 52 Week Low | $6.81 | N/A |
| 52 Week High | $53.25 | N/A |
| Indicator | DOGZ | XOMAO |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 54.90 |
| Support Level | $10.60 | $24.86 |
| Resistance Level | $11.74 | $25.58 |
| Average True Range (ATR) | 0.59 | 0.17 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 2.63 | 86.18 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.